期刊
SCIENTIFIC REPORTS
卷 11, 期 1, 页码 -出版社
NATURE PORTFOLIO
DOI: 10.1038/s41598-021-83755-3
关键词
-
资金
- Lund University
- UK Medical Research Council in the MRC Centre for Molecular Bacteriology and Infection, Imperial College London
- Swedish Heart-Lung Foundation [20200378]
- Alfred Osterlunds Foundation
- Royal Physiographic Society of Lund
- Swedish Research Council
- European Union [604182]
- MRC [MR/P028225/1] Funding Source: UKRI
- Swedish Heart-Lung Foundation [20200378] Funding Source: Swedish Heart-Lung Foundation
A fungal peptide was found to effectively reduce tuberculosis load and synergize with current TB drugs. The peptide remained stable in circulation and showed efficacy against drug-resistant bacteria.
Alternative ways to prevent and treat infectious diseases are needed. Previously, we identified a fungal peptide, NZX, that was comparable to rifampicin in lowering M. tuberculosis load in a murine tuberculosis (TB) infection model. Here we assessed the potential synergy between this cationic host defence peptide (CHDP) and the current TB drugs and analysed its pharmacokinetics. We found additive effect of this peptide with isoniazid and ethambutol and confirmed these results with ethambutol in a murine TB-model. In vivo, the peptide remained stable in circulation and preserved lung structure better than ethambutol alone. Antibiotic resistance studies did not induce mutants with reduced susceptibility to the peptide. We further observed that this peptide was effective against nontuberculous mycobacteria (NTM), such as M. avium and M. abscessus, and several Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus. In conclusion, the presented data supports a role for this CHDP in the treatment of drug resistant organisms.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据